The emergence of biologics, targeting mechanisms like leukocyte trafficking inhibition (anti-integrin antibodies) or inflammatory cytokine blockade (anti-tumor necrosis factor, anti-interleukin 12/23), has revolutionized our capacity to attain clinical remission and endoscopic healing, consequently reducing the onset of IBD-associated complications (153). This evidence concerns the gene TNF and inflammatory bowel disease.